# Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions

Page: https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-malignancy-risk-in-patients-with-ra-and-the-evolution-of-jaki-prescriptions
Text version: https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-malignancy-risk-in-patients-with-ra-and-the-evolution-of-jaki-prescriptions.md
Podcast: [The IMID Forum](https://stenobird.com/podcast/the-imid-forum-981476)
Published: 2026-03-26T10:45:45+00:00
Episode link: https://soundcloud.com/imidforum/discussing-ra-malignancy-risk
Audio file: https://feeds.soundcloud.com/stream/2290385534-imidforum-discussing-ra-malignancy-risk.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-malignancy-risk-in-patients-with-ra-and-the-evolution-of-jaki-prescriptions
Duration seconds: 602

## Resource

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-malignancy-risk-in-patients-with-ra-and-the-evolution-of-jaki-prescriptions/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-malignancy-risk-in-patients-with-ra-and-the-evolution-of-jaki-prescriptions.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.